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Abstract
Background: Neurofibromatosis 1 (NF1), a common autosomal dominant disorder, was shown in one study to be
associated with a 15-year decrease in life expectancy. However, data on mortality in NF1 are limited. Our aim was
to evaluate mortality in a large retrospective cohort of NF1 patients seen in France between 1980 and 2006.
Methods: Consecutive NF1 patients referred to the National French Referral Center for Neurofibromatoses were
included. The standardized mortality ratio (SMR) with its 95% confidence interval (CI) was calculated as the ratio of
observed over expected numbers of deaths. We studied factors associated with death and causes of death.
Results: Between 1980 and 2006, 1895 NF1 patients were seen. Median follow-up was 6.8 years (range, 0.4-20.6).
Vital status was available for 1226 (65%) patients, of whom 1159 (94.5%) survived and 67 (5.5%) died. Overall
mortality was significantly increased in the NF1 cohort (SMR, 2.02; CI, 1.6-2.6; P <1 0
-4). The excess mortality
occurred among patients aged 10 to 20 years (SMR, 5.2; CI, 2.6-9.3; P <1 0
-4) and 20 to 40 years (SMR, 4.1; 2.8-5.8;
P <1 0
-4). Significant excess mortality was found in both males and females. In the 10-20 year age group, females
had a significant increase in mortality compared to males (SMR, 12.6; CI, 5.7-23.9; and SMR, 1.8; CI, 0.2-6.4;
respectively). The cause of death was available for 58 (86.6%) patients; malignant nerve sheath tumor was the main
cause of death (60%).
Conclusions: We found significantly increased SMRs indicating excess mortality in NF1 patients compared to the
general population. The definitive diagnosis of NF1 in all patients is a strength of our study, and the high rate of
death related to malignant transformation is consistent with previous work. The retrospective design and hospital-
based recruitment are limitations of our study. Mortality was significantly increased in NF1 patients aged 10 to 40
years and tended to be higher in females than in males.
Background
Neurofibromatosis 1 (NF1; MIM#162200) is an inherited
autosomal dominant disorder with an incidence of 1 in
2500-3000 births [1]. NF1 is fully penetrant by 8 years
of age. According to the National Institutes of Health
(NIH), the diagnosis of NF1 requires at least two of the
following seven criteria: six or more café-au-lait spots
measuring at least 5 mm in prepupertal patients and 15
mm in postpubertal patients, multiple axillary freckles,
two or more neurofibromas (NFs) of any type or one
plexiform neurofibroma, Lisch hamartomas, optic path-
way glioma, bone dysplasia, and at least one affected
first-degree relative [2]. The phenotype of NF1 varies
substantially across patients.
The NF1 gene on chromosome 17q11.2 encodes the
tumor suppressor protein neurofibromin. Loss of this
protein is associated with an increased risk of develop-
ing tumors [3]. In a 12-year follow-up study of 70 adult
NF1 patients in Sweden, life expectancy was decreased
by 15 years compared to the general population, and
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study in a Danish cohort of 212 patients diagnosed 42
years earlier showed excess mortality with an increase in
malignancies in the males but not in the females, com-
pared to the general population [5]. Several clinical fea-
tures such as internal or subcutaneous NFs have been
shown to predict mortality in NF1 patients [6,7]. In a
cohort of 448 NF1 patients in the UK, the overall risk of
cancer was increased 2.7-fold compared to the general
population, and malignant peripheral nerve sheath
tumor (MPNST) was the leading cause of death [8]. A
proportional mortality study based on death certificate
data in the US from 1983 to 1997 demonstrated that
NF1 patients were 34 times more likely to have a malig-
nant connective or soft tissue neoplasm listed on their
death certificate than individuals without NF1 persons
(proportional mortality rate, 34.3; 95% confidence inter-
val [95%CI], 30.8-38) [9]. This study also showed an
about 15-year decrease in life expectancy in NF1
patients [9].
Nevertheless, data on mortality in NF1 are limited.
Our aim was to evaluate mortality in a large cohort of
patients with NF1 seen in France between 1980 and
2006. We computed standardized mortality ratios
(SMRs). We evaluated risk factors for death and causes
of death.
Patients and Methods
Definitions and study cohort
The study cohort was composed of consecutive patients
meeting NIH criteria for NF1 [2] who were referred to
the hospital departments of the Paris conurbation that
constitute the National French Referral Center for
Neurofibromatoses (dermatology departments at the
Henri Mondor and Necker-Enfants Malades hospitals
and neuropediatric department at the Trousseau hospi-
tal). We identified NF1 patients referred to these depart-
ments between January 1, 1980, and December 31, 2006,
in the NF1 Network Database maintained by the
National French Hospital Database (PMSI). Data from
all sources were linked and compared to eliminate
duplications and resolve discrepancies.
The study was approved by the Ile-de-France IX ethics
committee, Paris, France. The study complied with
Helsinki guidelines.
Data collection
For each patient, age at the beginning of the study per-
iod, sex, and clinical features were abstracted from the
medical charts and/or database. Detailed information
was available on the cardinal dermatological features of
NF1 (café-au-lait spots, freckles, Lisch nodules, and
cutaneous and plexiform neurofibromas). We also
recorded the following features as present or absent:
orthopedic complications (scoliosis and pseudoathrosis),
neurological abnormalities (hydrocephalus and high T2
signal intensity lesions on magnetic resonance imaging
of the brain), and renal artery stenosis. We recorded all
available data on tumors known to occur frequently in
NF1 patients (central nervous systems tumors, MPNSTs,
and pheochromocytomas).
Mortality assessment
Our goal was to determine vital status as of December
31, 2006. We first consulted the medical records and
network database. Then, we searched the National
French Mortality Database (INSERM CépiDC) for infor-
mation on patients whose place of birth was known; we
checked this information by calling the town hall of the
place of birth. Finally, we sought to contact patients by
phone and mail. Patients whose vital status was still
unknown after these three steps were classified as hav-
ing an unknown vital status (unknownVS group) and
other patients as having a known vital status (knownVS
group) (Figure 1).
Statistical analysis
Data were double entered and analyzed using STATA
software version 11 (Stata Corporation, College Station,
TX). Quantitative variables are reported as median
(range) and qualitative variables as number (%).
We compared the unknownVS and knownVS groups
using univariate analysis (chi-square test, or Fisher exact
test where appropriate, and nonparametric Mann-Whit-
ney test). Because age influences the prevalence and
number of NF1 features as café-au-lait spots and neuro-
fibromas, we computed age-adjusted odds ratios (aORs)
with their 95% confidence intervals (95%CIs) separately
for each variable. In the knownVS group, we computed
the standardized mortality ratio (SMR) as the ratio of
observed over expected deaths. SMR values greater than
1 with a CI that does not include 1 indicate excess mor-
tality. The expected number of deaths was obtained by
applying the mortality rates in France from 1980 to
2006 (by 5-year age groups and 5-year calendar periods,
separately in females and males) to the appropriate per-
son-years in the cohort. We considered the following
age groups: younger than 10 years, 10-20 years, 20-40
years, 40-60 years, and 60 years or older. The 95%CI of
the SMR was computed assuming a Poisson distribution
[10]. The chi-square test of dispersion of the Poisson
distribution was calculated. Sensitivity analyses were
performed. First, to avoid overestimation of mortality,
we computed the SMR for the overall cohort, assuming
that patients in the unknownVS group were alive on
December 31, 2006. Second, to minimize survivorship
bias (bias related to underestimation of mortality in
childhood due to patient attrition), we computed the
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Page 2 of 8NF1 patients included in the cohort 
from 1980 to 2006
n=1895
Vital status from medical records and
database
Place of birth
Phone or mail contact 
Unknown vital status, n=669 (35.3%)
Unknown, n=1 348 Known, n=547
Unknown, n=980 Known, n=368
No answer, n=669
Answer, n=311
Known vital status, n=1226 (64.7%)
Deceased
n=67 (5.5%)
Alive
n=1159 (94.5%)
Figure 1 Flow chart of the vital status of patients with NF1 cohort seen between 1980 and 2005.
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the beginning of our study period.
Results
Study cohort
Between January 1, 1980, and December 31, 2006, 1895
NF1 patients were seen at the National French Referral
Center for Neurofibromatoses. Their median follow-up
was 6.8 years [0.4-20.6]. At inclusion, median age was
17.7 [0-76] years, and 549 (44.8%) patients were younger
than 18 years (Table 1). At the end of the study period,
median age was 25.9 years [2-82].
Vital status was known for 1226 (65%) of the 1895
patients (Figure 1). At last follow-up, patients in the
unknownVS group had a median age of 25.4 years [0.2-
68] (Table 1). Compared to the unknownVS group, the
knownVS group had significantly higher prevalence of
freckles (aOR,1.7; 95%CI, 1.3-2.2) and MPNSTs (aOR,
2.7; 95%CI, 1.6-4.7) (Table 1). The prevalence of optic
pathway gliomas was nonsignificantly higher in the
knownVS group (OR, 1.3; 95% CI, 0.9-1.7; P = 0.11).
Of the 1226 patients in the knownVS group, 1 159
(94.5%) survived and 67 (5.5%) died.
Causes of death
The median age at death was 31.7 years [0-79.9], and
46.3% of patients who died were males. We did not
reported any death from the same family. Compared to
survivors, nonsurvivors had non significantly fewer
café-au-lait spots (aOR, 0.6; 95%CI, 0.3-1.1]) and signifi-
c a n t l ym o r en e u r o f i b r o m a s( a O R ,3 . 1 ;9 5 % C I ,1 . 2 - 8 . 4 ) ,
p l e x i f o r mn e u r o f i b r o m a s( a O R ,1 . 8 ;9 5 % C I ,1 . 1 - 3 . 0 ) ,
MPNSTs (aOR, 31.2; 95%CI, 17.4-55.9,) and pheochro-
mocytomas (aOR, 4.3; 95%CI, 1.1-16.3; Table 2).
The cause of death was known for 58 (86.6%) patients
and was related to NF1 in 56 (96.6%) of them. These
fatal complications of NF1 included MPNSTs (n = 33,
60%), central nervous system tumors (n = 8, 14%), spinal
cord compression by neurofibromas (n = 2, 3%), organ
compression by neurofibromas (n = 5, 9%), and pheo-
chromocytomas (n = 2, 3%).
Standardized mortality ratios
Compared to the general population, overall mortality
was significantly increased in the NF1 cohort (SMR, 2.02;
95%CI, 1.6-2.6; P <1 0
-4). The excess mortality was found
in two age groups, 10-20 years (SMR, 5.2; 95%CI, 2.6-9.3;
P <1 0
-4)a n d2 0 - 4 0y e a r s( S M R ,4 . 1 ;9 5 % C I ,2 . 8 - 5 . 8 ;P <
10
-4 ; Table 3). Significant excess mortality was observed
i nb o t hm a l e s( S M R ,1 . 8 ;9 5 %C I ,1 . 2 - 2 . 5 ;P = 0.01) and
females (SMR, 2.9; 95%CI: 2.0-4.0; P <1 0
-4 ; Table 4). In
the 10-20 year age group, mortality is higher in females
(SMR, 12.6; 95%CI, 5.7-23.9) than in males (SMR, 1.8;
95%CI: 0.2-6.4).
Assuming that patients in the unknownVS group were
alive at last follow-up did not substantially change the
Table 1 Characteristics of the NF1 patients according to whether their vital status was known or unknown
Clinical features* KnownVS group n = 1226
No (%)†
UnknownVS group
No (%)†
OR (95%CI) ‡ P value
Age, years (n = 1893) 25.9 [2-82]□ 25.4 [0.2-68]□ - 0.19
Male gender (n = 1 894) 579 (47) 304 (46) 0.9 (0.8-1.1) 0.57
Familial case (n = 1382) 515 (57) 278 (57) 1.0 (0.8-1.3) 0.95
At least 6 café-au-lait spots (n = 1889) 1 046 (86) 584 (87) 0.9 (0.7-1.2) 0.56
Freckles (n = 1 871) 1 043 (86) 509 (78) 1.7 (1.3-2.2) <10
-4
Neurofibromas (n = 1879) 923 (76) 495 (75) 1.0 (0.8-1.3) 0.87
Plexiform neurofibromas (n = 1865) 361 (30) 175 (27) 1.2 (0.9-1.4) 0.20
Lisch nodules (n = 1463) 382 (40) 204 (40) 1.1 (0.8-1.2) 0.87
Renal artery stenosis (n = 1361) 5 (1) 3 (1) 0.7 (0.2-3.1) 0.70
Scoliosis (n = 1373) 231 (25) 104 (24) 1.1 (0.8-1.4) 0.72
Nonunion (n = 1835) 45 (4) 20 (3) 1.2 (0.7-2.0) 0.57
Hydrocephalus (n = 1827) 32 (3) 23 (4) 0.7 (0.4-1.2) 0.22
OBNI (n = 801) 210 (40) 105 (38) 1.0 (0.7-1.4) 0.96
Optic pathway glioma (n = 1812) 161 (14) 69 (11) 1.3 (0.9-1.7) 0.11
MPNSTs (n = 1842) 80 (7) 16 (3) 2.7 (1.6-4.7) <10
-4
Pheochromocytoma (n = 1836) 13 (1) 7 (1) 1.3 (0.5-3.7) 0.61
Abbreviations: VS, vital status; OR, odds ratio; 95%CI, 95% confidence interval; OBNI, high T2-signal intensity lesions on magnetic resonance imaging of the brain;
MPNST, malignant peripheral nerve sheath tumor.
* Values in parentheses are the numbers of patients for whom data were available.
□Age at the end of the study period in patients whose vital status was known and age at last follow-up in those whose vital status was unknown status
† Percentages may not total 100, because of missing data.
‡The ORs were adjusted for age.
Data are numbers (%) or median [range].
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3.3; 95%CI, 1.6-5.8; P = 0.01) or 20 to 40 years (SMR,
2.4; 95%CI, 1.6-3.4; P = 0.001). When we confined the
analysis to the 633 patients born after January 1, 1980,
we found excess mortality inp a t i e n t sa g e d1 0t o3 0
years (SMR, 3.9; 95%CI, 2.3-6.3; P <1 0
-4). The excess
mortality in this subgroup seemed higher than in the
overall cohort.
Discussion
Significant excess mortality was found in our overall
cohort and in the subgroups aged 10 to 20 and 20 to 40
years. We did not find excess mortality in the subgroups
aged more than 40. It could be related to lack of power
due to a very low number of persons over 60. Excess
mortality was significant in both females and males; in
the 10-20 year age group, excess mortality was signifi-
cantly higher in the females than in the males. The vast
majority of deaths were due to malignancies and other
complications of NF1.
We retrospectively identified consecutive NF1 patients
referred to the French National Referral Center for Neu-
rofibromatoses. An important strength of our study is
that all patients had a definitive diagnosis of NF1.
Furthermore, the overall prevalence of NF1 manifesta-
tions in our cohort was consistent with previous reports,
[11] indicating that our cohort was representative of the
NF1 population. We used multiple sources of informa-
tion to determine vital status. Nevertheless, vital status
was known for only about two-thirds of the patients,
which may have resulted in information bias. However,
to avoid overestimating mortality, we conducted an ana-
lysis assuming that all patients whose vital status was
unknown were alive at last follow-up. We again found
significant excess mortality among NF1 patients aged 10
to 40 years compared to the general population.
Table 2 Characteristics of the survivors and nonsurvivors among the 1226 NF1 patients whose vital status was known
Clinical features* Survivors
n = 1159
No (%)†
Nonsurvivors
n=6 7
No (%)†
OR
(95%CI)‡
P value*
Age, years, median [range] 25.5 [2-74] 31.7 [0-80] - 0.008
Male gender 548 (47) 31 (46) 1.0 (0.6-1.7) 0.98
Familial case (n = 897) 498 (58) 17 (53) 0.7 (0.3-1.4) 0.62
At least 6 café-au-lait spots (1220) 998 (86) 48 (74) 0.6 (0.3-1.1) 0.07
Freckles (n = 1217) 985 (86) 58 (88) 1.1 (0.5-2.4) 0.74
Neurofibromas (n = 1215) 863 (75) 60 (90) 3.1 (1.2-8.4 0.02
Plexiform neurofibromas (n = 1209) 333 (29) 28 (42) 1.8 (1.1-3.0) 0.02
Lisch nodules (n = 954) 366 (40) 16 (40) 0.9 (0.5-1.9) 0.89
Renal artery stenosis (n = 601) 5 (1) 0 (0) - 0.60
Scoliosis (n = 934) 222 (25) 9 (18) 0.6 (0.3-1.3) 0.23
Nonunion (n = 1 194) 43 (4) 2 (3) 0.7 (0.2-3.2) 0.70
Hydrocephalus (n = 1 190) 31 (3) 1 (2) 0.6 (0.1-4.4) 0.60
OBNI (n = 526) 202 (40) 8 (30) 0.6 (0.3-1.5) 0.30
Optic pathway glioma (n = 1 172) 151 (13) 11 (17) 1.2 (0.6-2.6) 0.58
MPNST (n = 1198) 44 (4) 36 (55) 31.2 (17.4-55.9) <10
-4
Pheochromocytoma (n = 1193) 10 (1) 3 (5) 4.3 (1.1-16.3) 0.03
Abbreviations: OR, odds ratio; 95%CI, 95% confidence interval; OBNI, high T2-signal intensity lesions on magnetic resonance imaging of the brain; MPNST,
malignant peripheral nerve sheath tumor.
*Values in parentheses are the numbers of patients for whom data were available.
†Percentages may not total 100, because of missing data.
‡The ORS were adjusted for age.
Data are numbers (%) or median [range].
Table 3 Number of deaths (n) and SMRs among the NF1 patients by age group
Age, years Person- Years Observed Deaths Expected Deaths SMR 95%CI
<10 11 905.5 4 4.2 0.95 0.3-2.4
10 to <20 8875 11 2.1 5.2 2.6-9.3
20 to <40 10 395 31 7.6 4.1 2.8-5.8
40 to <60 3657.5 11 11.6 0.9 0.5-1.7
≥60 480 10 7.7 1.3 0.6-2.4
SMR, standardized mortality ratio (observed deaths/expected deaths); 95%CI, 95% confidence interval.
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design, which may have resulted in survivorship bias
with underestimation of mortality due to higher values
for both patient attrition and mortality in the older
patients. However, when we conducted an analysis con-
fined to patients born after the beginning of our study
period, we still found significant excess mortality com-
pared to the general population. Finally, our hospital-
based recruitment may have led to a bias toward
patients with more severe forms of NF1 and, therefore,
to overestimation of the SMR. However, our findings
are consistent with previous reports [4,5,9].
Among the 58 patients who died and in whom the
cause of death was known, 56 died from NF1 complica-
tions, chiefly malignancies (MPNSTs in 60% and cere-
bral tumors in 14%). Our results are consistent with
those of a prospective study of the incidence of cancer
in NF1 patients in the UK [8]. In this study, the overall
risk of cancer was 2.7 times higher in NF1 patients than
in the general population, and increases were found in
central nervous system tumors and connective tissue
tumors, as well as in breast cancer in women younger
than 50 years (standardized incidence ratio, 4; 95%CI,
1.1-10.3). The risk of mortality related to breast cancer
was not reported. In our study, we did not assess the
prevalence of breast cancer, which was not the reported
cause of death in any of the patients. Similarly, in a
death certificate study done in the US, NF1 patients
were 34 times more likely to have a malignant connec-
tive or other soft tissue neoplasm listed on their death
certificate than patients without NF1 [9]. The propor-
tionate mortality ratios for malignancies were 6.07 for
patients who died between 10 and 19 years of age and
4.93 for those who died between 20 and 29 years of age.
Proportionate mortality ratios were also increased for
central nervous system tumors and vascular disease. The
authors concluded that the impact of NF1 on mortality
from malignancies and vascular disease was focused on
patients younger than 40 years of age [9]. In our cohort,
cardiovascular disease was not reported as a cause of
death. Our chart review did not assess cardiovascular
morbidity and we also did not estimate the cardiovascu-
lar risk in NF1 patients.
In our study, MPNSTs were the leading cause of death
(n = 33, 60%). NF1 is widely recognized as a risk factor
for MPNSTs, and the lifetime risk of MPNSTs in NF1
patients has been estimated at 8%-13% [1,12]. In an ear-
lier study, we also found that MPNST was the main
cause of death and that risk factors for MPNST were
the absence of cutaneous neurofibromas, presence of at
least two subcutaneous neurofibromas, and facial asym-
metry [6]. Further studies confirmed that subcutaneous
neurofibromas predicted mortality (OR, 3.6; 95%CI, 1.2-
11.3) [7] and that internal plexiform neurofibromas
were strongly associated with MPNST (OR, 18.06; 95%
CI, 4.55-73.4) [13]. We did not have detailed informa-
tion on these features in our patients and were therefore
unable to assess their potential relationship to mortality.
Nonsurvivors had fewer café-au-lait spots than did sur-
vivors. Furthermore, excess mortality was confined to
patients aged 10 to 40 years. These two variables are
among the four used in the NF1 score for predicting
internal neurofibromas (age ≤30 years, fewer than six
café-au-lait spots, no cutaneous neurofibromas, and two
or more subcutaneous neurofibromas) [14]. Internal
neurofibromas are strongly associated with MPNSTs
[14].
In our study, median age at death was 31.7 years
[0-77.9], that is, considerably younger than in previous
studies. However, our patients were young, with a med-
ian age of 25.9 years at the time of the analysis. In a
Japanese death certificate study, mean age at death from
neurofibromatosis was 43 years, but NF1 and NF-2 were
not clearly separated [15]. In a death certificate study
done in the US, mean age at death in NF1 patients was
54.4 years, that is, 15.7 years younger than in the
g e n e r a lp o p u l a t i o n[ 9 ] .I nt h i ss t u d y ,t h ea u t h o r su s e d
multiple-cause mortality files compiled from US death
certificates and identified 3770 cases of presumed NF1
among the 32 722 122 deaths recorded from 1983 to
1997 [9].
Mean age at death in our study was lower in females
than males, in keeping with an earlier study [5]. We also
found that excess mortality was significantly greater in
females than in males between 10 and 20 years of age. Sex
hormones may affect the NF1 phenotype. Immunostaining
Table 4 Number of deaths (n) and SMRs among the NF1 patients, by age categories (years), by sex
Male Female
Age,
years
Person-
Years
Observed
Deaths
Expected
Deaths
SMR 95%CI Person-
Years
Observed
Deaths
Expected
Deaths
SMR 95%CI
<10 5569.5 1 1.8 0.6 0.01-3.1 6336 3 1.8 1.7 0.3-4.8
10 to <20 4000 2 1.1 1.8 0.2-6.4 4875 9 0.7 12.6 5.7-23.9
20 to <40 4262.5 19 4.4 4.3 2.6-6.7 6132.5 12 2.6 4.7 2.4-8.2
40 to <60 1272.5 5 5.5 0.9 0.3-2.1 2385 6 4.8 1.3 0.5-2.7
≥60 162.5 4 4.8 0.8 0.2-2.1 317.5 6 2.7 2.3 0.8-4.9
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bromas [16]. Furthermore, orthotopic xenografts of an
immortal human NF1-derived Schwann cell line into
the sciatic nerves of female mice with severe combined
immunodeficiency produced MPNSTs, and tumor cell
proliferation was decreased in ovariectomized mice
and restored by estrogen or progesterone replacement
therapy [17]. Additional experiments by the same
group supported a role for estrogen and progesterone
on the growth of MPNST obtained by xenografting
[18]. Finally, in vitro and in vivo studies on MPNST
cell lines or MPNST xenografts showed that tamoxifen
inhibited malignant cell growth in an estrogen-
receptor-independent manner [1,19].
In conclusion, our evaluation of SMRs indicates signif-
icant excess mortality in NF1 patients compared to the
general population. Although the retrospective design
and hospital-based recruitment are limitations of our
study, the predominance of cancer among causes of
death is consistent with earlier work. We found that
excess mortality was confined to the 10-40 year age
group and that females in the 10-20 year age group had
significantly greater excess mortality than males. Addi-
tional studies following our cohort ageing might accu-
rately assess mortality above 40 years in NF1 patients.
Abbreviations
NF1: Neurofibromatosis 1; NF-2: Neurofibromatosis 2; NFs: Neurofibromas;
MPNST: Malignant peripheral Nerve sheath tumor; CI: Confident Interval;
aOR: adjusted Odds Ratio; SMR: Standardized mortality ratios
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